After this work has been submitted, two additional reports from the Hellstrand group independently described an expansion of CD56brightCD16neg cells in HDC plus IL-2 treated AML patients [46, 47], but the CD56brightCD16low cells were not separately investigated in these studies. Here, IL2 is linked to acute myeloid leukemia.